We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Low-Cost Technology Diagnoses Influenza Early

By LabMedica International staff writers
Posted on 25 Sep 2013
A novel technology is showing promise as the basis for a much-needed home test to diagnose influenza quickly, before the window for taking antiviral drugs closes. More...


A fast, inexpensive diagnostic test, similar to the quick throat swabs for Streptococcus pneumoniae tests, is especially important for influenza, which causes widespread illness and an average of 36,000 deaths annually in the USA alone.

A scientist at the Georgia State University (Atlanta, GA, USA) and a colleague at the University of Cincinnati (OH, USA) launched a search for a fundamental approach for diagnosing influenza and other viral disease because of drawbacks with existing tests. Those tests can produce results in about 15 minutes. However, they are expensive and sometimes give false negative results when the patient is infected with the influenza virus.

The influenza viruses have two major antigens, hemagglutinin and neuraminidase, which determine the specific strain of the virus. Changes in hemagglutinin and/or new combinations of hemagglutinin and neuraminidase signal the emergence of a new strain of virus. The novel technology uses various forms of carbohydrates that can capture the hemagglutinin and neuraminidase, and via a color change or other signal, indicate both infection and the specific type or strain of influenza virus. Information on the strain would be important, enabling doctors to pick the most effective antiviral drug. The innovative approach has other potential advantages, including quicker results, lower cost, and greater reliability.

Influenza binds to N-acetyl neuraminic acid or sialic acid present on the surface of cells. The investigators are developing robust synthetic analogs of sialic acids that can be used as capture and reporter molecules in point of care diagnostics. The synthesis, stability and the ability of these molecules to capture influenza virus at room temperature without the addition of inhibitors was the crux of the technology. The approach so far is living up to expectations, with laboratory experiments verifying that it can detect influenza viruses. The team of Suri Iyer, PhD, and Allison Weiss, PhD, plan to move ahead in the autumn with tests on samples taken from human volunteers. The study was presented at the 246th National Meeting & Exposition of the American Chemical Society held September 8-12, 2013 in Indianapolis (IN, USA).

Related Links:

Georgia State University
University of Cincinnati



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.